Evidence map›Paper›PMID 29276625›Full record

ArticlePilot and feasibility studies2017

Epicardial delivery of autologous atrial appendage micrografts during coronary artery bypass surgery-safety and feasibility study.

Annu Nummi, Tuomo Nieminen, Tommi Pätilä, Milla Lampinen, Miia L Lehtinen, Sari Kivistö, Miia Holmström, Erika Wilkman, Kari Teittinen, Mika Laine and 8 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02672163 nacompletednot on this map

Epicardial Delivery of Autologous Atrial Appendage Micrografts During Coronary Artery Bypass Surgery - Safety and Feasibility Study

TypeinterventionalSponsorHelsinki University Central HospitalRan2016 to 2019Enrolled36ConditionsHeart FailureArmsCABG surgery, AADC therapy
NCT05632432 narecruitingnot on this mapstarted 2024, after this paper: background citation

Autologous Atrial Appendage Micrografts Transplanted During Coronary Artery Bypass Surgery: the AAMS2 Randomized, Double-blinded, and Placebo-controlled Trial

TypeinterventionalSponsorHospital District of Helsinki and UusimaaRan2024 to 2026Enrolled50ConditionsIschemic Heart Disease, Ischemic Cardiomyopathy, Heart Failure, Systolic, Heart Failure NYHA Class IIIArmsEpicardial AAMs-patch transplantation, RNA-stabilized whole blood sampling, Plasma sampling, Transthoracic echocardiography, Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Tissue regeneration: an overview from stem cells to micrografts.The Journal of international medical research · 2020
    Review
  8. Stem Cell Therapies in Cardiovascular Disease.Journal of cardiothoracic and vascular anesthesia · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Annu NummiHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tuomo NieminenHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tommi PätiläPediatric Cardiac Surgery, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Milla LampinenDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Miia L LehtinenHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Sari KivistöHUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Miia HolmströmHUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Erika WilkmanDepartment of Anesthesiology and Intensive Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kari TeittinenHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mika LaineHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Juha SinisaloHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Markku KupariHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Esko KankuriDepartment of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Tatu JuvonenHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Antti VentoHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Raili SuojarantaDepartment of Anesthesiology and Intensive Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ari HarjulaHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
AADC consortium
University of Helsinki · FIHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe atrial appendages are a tissue reservoir for cardiac stem cells. During on-pump coronary artery bypass graft (CABG) surgery, part of the right atrial appendage can be excised upon insertion of the right atrial cannula of the heart-lung machine. In the operating room, the removed tissue can be easily cut into micrografts for transplantation. This trial aims to assess the safety and feasibility of epicardial transplantation of atrial appendage micrografts in patients undergoing CABG surgery. METHODS/

designAutologous cardiac micrografts are made from leftover right atrial appendage during CABG of 6 patients. Atrial appendage is mechanically processed to micrografts consisting of atrial appendage-derived cells (AADCs) and their extracellular matrix (ECM). The micrografts are epicardially transplanted in a fibrin gel and covered with a tissue-engineered ECM sheet. Parameters including echocardiography-reflecting cardiac insufficiency-are studied pre- and post-operatively as well as at 3 and 6 months of the follow-up. Cardiac functional magnetic resonance imaging is performed preoperatively and at 6-month follow-up. The primary outcome measures are patient safety in terms of hemodynamic and cardiac function over time and feasibility of therapy administration in a clinical setting. Secondary outcome measures are left ventricular wall thickness, change in the amount of myocardial scar tissue, changes in left ventricular ejection fraction, plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, New York Heart Association class, days in hospital, and changes in the quality of life. Twenty patients undergoing routine CAGB surgery will be recruited to serve as a control group. DISCUSSION: This study aims to address the surgical feasibility and patient safety of epicardially delivered atrial appendage micrografts during CABG surgery. Delivery of autologous micrografts and AADCs has potential applications for cell and cell-based gene therapies.

trial registrationClinicalTrials.gov Identifier: NCT02672163. Date of registration: 02.02.2016.

Indexed as

Atrial appendageAutologous micrograftsCell therapyCoronary artery bypass surgeryEpicardial cell deliveryHeart failure

Identifiers

PMID29276625
PMCPMC5738681
OpenAlexW2781235243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.